ASH 2021 | Atezolizumab with R-GEMOX in patients with transformed DLBCL
Alex Herrera
• 13 Dec 2021
Alex Herrera, MD, City of Hope, Duarte, CA, shares an update on the study evaluating the addition of the PD-L1 inhibitor, atezolizumab, to immunogenic chemoimmunotherapy, rituximab with gemcitabine and oxaliplatin (R-GEMOX) in patients with relapsed/refractory (R/R) transformed diffuse large b-cell lymphoma (DLBCL) or Richter transformation (RT) from chronic lymphocytic leukemia (CLL). While patients with RT did not show outstanding responses, the patients with transformed follicular lymphoma and transformed marginal zone lymphoma presented good response rates. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
